BioPharma DiveOriginal article
FDA clears first generic radioligand drug; Sionna turns to layoffs
RegulatoryapprovedLutatheraLutathera generic equivalentRNAi drug (novel)Positive
AI Analysis
Summary
The FDA has cleared the first generic radioligand equivalent, a copycat of Lutathera, marking a regulatory milestone for the drug class. Sionna is conducting layoffs, while Novo Nordisk dropped "Nordisk" from its name and a novel RNAi drug showed early promise.
Outcome Details
FDA clears first generic radioligand equivalent
Importance:6/10
Sentiment:
0.30
FDA approvalgeneric drugradioligandLutatheralayoffsRNAi
Related Companies
Read the original article
Published by BioPharma Dive on September 15, 2026 9:13 PM